|Bid||100.9800 x 800|
|Ask||101.3900 x 800|
|Day's Range||99.73 - 102.22|
|52 Week Range||75.20 - 137.95|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||19.81|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||134.33|
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
USANA Health Sciences Inc NYSE:USNAView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for USNA with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding USNA totaled $2.45 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Services sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! USANA Health Sciences, Inc. (NYSE:USNA) is aRead More...
The Salt Lake City-based company said it had net income of $1.32 per share. The nutritional supplement maker posted revenue of $299 million in the period. For the year, the company reported profit of $126.2 ...
SALT LAKE CITY-- -- Record fiscal year net sales of $1.189 billion, an increase of 13.6% Record fiscal year net earnings of $126.2 million, or $5.12 per share Fourth quarter net sales of $299.0 million, an increase of 9.5% year-over-year Fourth quarter net earnings of $32.3 million, or $1.32 per share USANA Health Sciences, Inc. today announced financial results for its fiscal fourth quarter and full-year ...
Ten-time Emmy® award-winning show will be available on multiple Chinese digital platforms SALT LAKE CITY , Jan. 15, 2019 /PRNewswire/ -- Aofei Media now distributes new episodes of The Dr. Oz Show in China ...
Today we'll look at USANA Health Sciences, Inc. (NYSE:USNA) and reflect on its potential as an investment. Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give Read More...
USANA Health Sciences, Inc. today announced that fourth quarter and full-year results will be released after the close of market Tuesday, February 5, 2019. Shortly following the issuance of the Company’s earnings release, the Company will post a “Management Commentary, Results and Outlook” document on the Company’s website under the “Investor Relations” section of the site.
USANA Health Sciences, Inc. (USNA) today announced the appointment of Peggie Pelosi to the company’s board of directors effective December 19, 2018. Ms. Pelosi joins the board as an independent director and brings expertise in corporate social responsibility and sustainability, as well as direct selling. The USANA board now has eight members, five of whom are independent.
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients’ money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
BiOmega™ Passes Rigorous Testing by ConsumerLab.com SALT LAKE CITY , Dec. 5, 2018 /PRNewswire/ -- Global health and wellness giant USANA Health Sciences has, once again, been recognized with a seal of ...
SALT LAKE CITY, Dec. 4, 2018 /PRNewswire/ -- USANA, The Cellular Nutrition Company, has partnered with some of the world's most skilled winter Olympians since 1999—dominating the winter field with partnerships across seven national governing bodies throughout the United States and Canada. USANA will provide the National and World Team members its NSF and LGC tested supplements as they prepare for Tokyo and beyond. Learn more about the thousands of elite athletes who trust their health to USANA at teamusana.com.
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We’ll look at USANA Health Sciences Inc’s (NYSE:USNA) P/E ratio and Read More...
The Asia-Pacific region, particularly India, is generating strong sales and is likely to support its top line in the coming quarters. Strong sales and higher margins are expected to support the company’s earnings. About 60.0% of the analysts covering Herbalife stock suggest a “buy,” and 40.0% of the analysts recommend a “hold.” Wall Street has a consensus target price of $63 on Herbalife stock, which indicates an upside potential of 15.2% based on its closing price of $54.69 on October 30.
Herbalife stock (HLF) rose 1.6% in after-hours trading following the company’s robust third-quarter results on October 30. Herbalife sustained its strong sales and earnings growth momentum. Driven by the company’s strong top-line performance, its bottom line recorded stellar YoY growth and handily exceeded analysts’ estimates.